cyrilzakka/clinical-trials huggingface dataset:
Ultra Violet-C Light Evaluation as an Adjunct to Removing Multi-Drug Resistant Organisms (UVCLEAR-MDRO)

This study examines the impact of UV-C light disinfection as an adjunct to routine daily and discharge patient room cleaning on patient infection and colonization with hospital associated bacteria.

Patient rooms are counted as enrolled since consent was waived and the number of participants is unknown. Total of 83 rooms.

Effective cleaning of the patient environment (the patient room during hospital stay) is subject to human factors and unfortunately is often inconsistent or inadequate. Patient rooms that have residual bacteria after routine environmental cleaning can act as reservoirs for multidrug-resistant organisms (MDROs) and contribute to the spread of MDROs from patient to patient. In the setting of an increased focus on Healthcare-associated Infections such as Clostridium difficile (C. difficile) and multidrug-resistant Gram negative and Gram positive organisms such as carbapenem-resistant Enterobacteriaceae (CRE), vancomycin-resistant Enterococcus (VRE) and methicillin-resistant Staphlococcus aureus (MRSA), Ultra-Violet C (UV-C) light has been shown to be a safe, effective way to decrease the burden of MDROs in patient rooms. However, studies examining the effectiveness of UV-C light when used post daily and discharge patient room cleaning are lacking.

This study is a cluster, randomized, two-period cross over trial to investigate the relationship between environmental decontamination with UV-C light and transmission of VRE and other healthcare-associated bacteria. It investigates the hypothesis that UV-C in addition to daily cleaning leads to decreased patient acquisition of healthcare-associated bacteria.

This study is important to further advance hospital-based infection prevention knowledge of the impact of UV-C light for environmental cleaning.

Patient rooms are counted as enrolled since consent was waived and the number of participants is unknown. Total of 83 rooms.

Eligibility Criteria:
Inclusion Criteria:

* Patient rooms in pre-selected hospital units within Johns Hopkins Hospital

Exclusion Criteria:

* None, intervention is at level of the hospital unit, not the patient
Efficacy Rate of Unipolar Polarity Switch for Lesion Assessment in Pulmonary Vein Isolation

The technique of intraprocedural electrogram morphology as a measure of lesion effectiveness in an attempt to achieve durable PVI, clearly led to shortened procedural time, radiation exposure, and superiority in outcomes, with the implementation of a reproducible, readily available intraprocedural tool that can be applied universally.

One initial study reported that unipolar atrial EGM modification was a useful end point for RF energy delivery. They compared 2 groups of patients with paroxysmal AF undergoing PVI facilitated by an electroanatomic mapping system, merged preprocedural LA computed tomographic scan, and a circular mapping catheter.

They were the first to use intraprocedural electrogram morphology as a measure of lesion effectiveness in an attempt to achieve durable PVI. The technique, clearly led to shortened procedural time, radiation exposure, and superiority in outcomes, with the implementation of a reproducible, readily available intraprocedural tool that can be applied universally.

As there is scant data is this area with lack of randomized human trials, planned on building and further validating evidence from Bortone et al in demonstrating that loss of unipolar negative component during PVI can serve a great adjuvant tool for achieving durability of PVI with overall lesser procedural time and no significant increase in adverse events.

Eligibility Criteria:
Inclusion Criteria:

* All Patients ≥ 18 years of age
* Undergoing pulmonary vein isolation for De-Novo Atrial Fibrillation.

Exclusion Criteria:

* Patients unable to give consent
* Who do not have De-novo AF.
The Effect of Self-made Fetal Movement and Position Tracking During Pregnancy on Maternal Attachment

This study was conducted to determine the effect of self-made fetal movement counting and fetal position tracking on maternal attachment in prenatal period.

The first attachment between mother and baby begins in the prenatal period. It is expected to increase as pregnancy progresses.The more the mother tries to communicate and interact with her baby, the stronger her attachment to her baby. The baby can be accepted by the mother as an individual, and the attachment between the mother and baby can increase.The early development of safe and positive attachment composes the basis of healthy development. In the later years of childhood, safe attachment is effective on healthy processes, such as being more positive, establishing close, constructive and respectful relationships, and a high sense of trust, while unsafe attachment is associated with emotional, social, physical and mental psychopathologies. The mother's touching her baby over her abdomen, trying to guess the parts of the baby, following baby movements, communicating with the baby by focusing and spending private time with the baby increase the physical and psychological contact with the baby. Fetal movement counting is defined as tracking uninterrupted fetal movements for at least 15-20 minutes by lying on the left side in a calm environment at any time during the day when this baby is awake. Fetal position tracking is described as trying to guess the parts of the baby by placing the mother's hand on the abdomen. In the literature, it is stated that prenatal attachment affects postpartum maternal attachment, contributes positively to infant care and provides rapid adaptation to motherhood. In addition, secure/insecure attachment styles are thought to be associated with postpartum depression. It is stated that the babies of mothers with strong prenatal attachment show healthier growth and development and even affect their personality positively in adulthood. In the literature, it is stated that the prenatal period can be an indicator of mother-infant interaction in the postpartum period.This study was carried out as a continuation of the previous study, NCT05313113 Clinical ID, to determine maternal attachment in the postpartum period of pregnant women whose fetal movement and position were followed.

Eligibility Criteria:
Inclusion Criteria:

* literate
* between the ages of 19-35
* Effective communication
* first pregnancy
* having a single fetus
* Pregnancy week between 24 and 28. between the ages of 19-35
* Effective communication
* first pregnancy
* having a single fetus
* Pregnancy week between 24 and 28.

Exclusion Criteria:

* Pregnancy using assisted reproductive techniques
* Having a risky pregnancy (preeclampsia, placenta previa, gestational diabetes etc.)
* Pregnant women with a chronic disease (heart, systemic, circulatory disorder, psychiatric, etc.) were not included in the study.
Biodistribution and Dosimetry of 99mTc-Duramycin

Conduct a first-in-human study in healthy volunteers to show safety, biodistribution and dosimetry of \[99mTc\]Duramycin.

Monocenter, prospective microdosing study in healthy volunteers. Healthy volunteers will undergo a \[99mTc\]Duramycin whole-body planar and abdominal SPECT scan at different time points after one iv injection of the radiotracer (1 h, 2h, 3h, 6h and 24h), while vital signs, urine and faces analysis will be checked. Blood samples will be taken at 12 different time points: 9 blood samples for dosimetry study and 3 blood samples will be subjected to clinical laboratory chemistry (renal and liver function chemistry, hematology, and blood coagulation parameters).

Eligibility Criteria:
Inclusion Criteria:

* Males (n=4) or females (n=4) age 18 years or older
* Stated willingness to comply with all study procedures and availability for the duration of the study.
* Ability to give study-specific written informed consent.

Exclusion Criteria:

* Pregnant or lactating females (positive pregnancy test)
* Metal implants (e.g. pacemakers, osteosynthesis material)
* Body weight \> 100 kg
* Severe claustrophobia
* Abnormal kidney or liver function tests
* Unable to comply with study requirements
Effects of Inspiratory Flow Waveforms on Preload

The clinical usefulness of inspiratory flow pattern manipulation during mechanical ventilation remains unclear. The aim of this study was to investigate the effects of different inspiratory flow waveforms, i.e. constant and decelerating, on cardiac preload in mechanically ventilated patients assessed by arterial pulse pressure variation (PPV) and inferior vena cava distensibility.

During mechanical ventilation the lungs can be inflated with different pressure and flow waveforms. Originally the piston-driven mechanical ventilators generated a quasi-sinusoidal flow waveform, whereas the newer electronically controlled ventilators can also produce constant and decelerating waveforms. According to several theoretical,animal and clinical studies,the inspiratory flow waveform affects the distribution of the inspired gas as well as respiratory mechanics and gas exchange. However, other studies failed to show any significant effect.But there is no study interested to the effects of inspiratory flow waveforms on cardiac preload. Thus, the clinical usefulness of inspiratory flow pattern manipulation remains unclear, though the capacity for selection of different inspiratory flow waveforms is provided by most modern, microprocessor-equipped ventilators. Therefore, the purpose of this study was to compare the effects of flow patterns (sinusoidal, constant and decelerating) on dynamic measurements of cardiac preload dependence such as arterial pulse pressure variation (ΔPP) and distensibility index of the inferior vena cava (dIVC).

Eligibility Criteria:
Inclusion Criteria:

* mechanical ventilation
* Volume AssistControl Ventilation
* sinus rhythm

Exclusion Criteria:

* pressure mode
* arrhythmia
Areas of Brain Responsible for Understanding American Sign Language

The human brain is made up of two halves called hemispheres. Each half of the brain is responsible for processing different kinds of information. Previous neuroimaging studies have shown that both the right and left hemispheres are involved when processing information given in American Sign Language (ASL). However, the study also showed that when processing spoken language, the left hemisphere was mostly involved.

Researchers would like to find out more about how the brain processes American Sign Language (ASL). This study is designed to determine if the right hemisphere is necessary for normal understanding of ASL.

The purpose of this protocol is to determine if the right hemisphere activation associated with perception of American Sign Language (ASL) in deaf subjects and in normal hearing individuals raised by deaf parents (who learned ASL before written English) is necessary for appropriate understanding of ASL.

Eligibility Criteria:
Subject age between 18 and 65 years.

Adult hearing offsprings of deaf parents.

Congenitally deaf individuals.

Intact hearing volunteers.

No subjects with personal or family history of seizures or other neurological or demyelinating disorders.

No pregnant women tested after urine pregnancy test.

No subjects with severe coronary disease.

No subjects with metal in the cranium except mouth.

No subjects with intracardiac lines and implanted medication pumps.

No subjects with increased intracranial pressure as evaluated by clinical means.

No subjects with cardiac pacemakers.

No subjects with an intake of neuroleptics.
Biomarkers in SCOTland CardiomyopatHy Registry (Bio-SCOTCH)

Genetic cardiomyopathy is increasingly recognised and can lead to heart failure, arrhythmia and sudden cardiac death. Some gene positive patients have rapidly progressive disease with high rates of heart failure and cardiac transplantation, while others present with SCD. Other gene positive patients will never develop cardiomyopathy. At present, we cannot distinguish between these groups and rely on expensive and labour-intensive surveillance by electrocardiography, echocardiography and sometimes cardiac magnetic resonance imaging.

This study will investigate existing and novel biomarkers (including blood, urine electrocardiographic and imaging) at various stages of disease in patients with a personal or family history of TTN, MYBPC3, LMNA, FLNC or DSP gene variant, which are known to cause cardiomyopathy.

There is a growing appreciation for the role that genetics play in the development of cardiomyopathy, which can lead to heart failure, arrhythmia and sudden cardiac death.

Increased use of genetic testing has identified numerous gene variants, which cause cardiomyopathy with dilated, hypertrophic, restrictive, non-dilated left ventricular and arrhythmogenic right ventricular phenotypes described.

Some gene variants cause a rapidly progressive cardiomyopathy with high rates of heart failure and cardiac transplantation, while others present with SCD, meaning that genotype-specific risk stratification and clinical surveillance is urgently needed. Some gene-positive individuals will never develop cardiomyopathy due to variable penetrance. At present, we cannot distinguish between these patients and therefore rely on expensive and labour-intensive surveillance by electrocardiography, echocardiography and sometimes cardiac magnetic resonance imaging. For every gene-positive affected individual with cardiomyopathy, cascade genetic testing will identify other gene-positive family members who are often asymptomatic and may not yet be affected.

A blood or urine-based biomarker that identifies pre-clinical disease or cardiomyopathy would allow for more efficient monitoring of gene positive people and could replace multiple, repeated electrocardiograms, echocardiograms and cardiac magnetic resonance imaging scans. A biomarker that accurately identifies pre-clinical cardiomyopathy could enable targeted early treatment. A biomarker that predicts future disease progression would be of high clinical value.

Eligibility Criteria:
Inclusion Criteria:

* Male or female ≥10 years of age
* Written informed consent / assent
* Pathogenic or likely pathogenic variant in a cardiomyopathy gene (TTN, LMNA, MYBPC3, DSP, FLNC) or undergoing predictive genetic testing (if negative these people would be invited to enter the control arm)

Exclusion Criteria:

* Unable to consent.
* Geographical / social reasons preventing attending study centre
* Unable to complete study assessments.
* Severe non-cardiac disease expected to reduce life expectancy \< 5 years
* Current participation in a blinded drug interventional trial (or treatment within 4 weeks)
Shared Decision Making to Address Racial Disparities in Oral Anticoagulation in NVAF

The study is a pilot analysis using a decision on the risk and benefits of oral anticoagulation for stroke reduction for patients with non-valvular atrial fibrillation. This study is a feasibility and acceptability analysis but will also measure preliminary effectiveness measures.

The investigator hypothesizes that a patient decision support tool will increase decision quality and secondarily increase the use of oral anticoagulation in Black patients with non-valvular atrial fibrillation.


Eligibility Criteria:
Inclusion Criteria:

* Black and White adults greater than or equal to 18 years of age
* Clinical diagnosis of NVAF
* CHA2DS2-VASc score greater than or equal to 2
* New patient visit for initiation of oral anticoagulation at primary care and cardiology clinics

Exclusion Criteria:

* Unable to speak English
* Unable to provide informed consent
Intraocular Pressure in Children With Acute Lymphoblastic Leukemia (ALL) Treated With High Dose Steroids

Childhood ALL patients are treated with high dose steroids. The study will follow the intraocular pressure of children treated in according to an AIEOP-BFM protocol, during the induction phase that will be compared to the pressure before treatment. Potential risk factors for developing elevated intraocular pressure will be estimated.

Children with ALL in Israel are treating according to the BFM ALL Protocol which contains high dose steroid therapy. One of the known side effects of high dose steroids is Intraocular hypertension, glaucoma, and even irreversible optic nerve injury. Early diagnosis of elevated intraocular pressure (IOP) and early therapeutic interventions might help to prevent future ocular damage.

The purpose of this study is to determine the risk of developing evaluate Intraocular pressure during high dose steroid therapy. If elevated IOP will be common enough, we will try to corelate the risk of elevated IOP with potential risk factors, such as initial IOP, WBC at diagnosis, etc.

Intraocular pressure will be measured by ophthalmologists using iCare devise: TONOPEN during general anesthesia at the day of diagnosis of ALL before steroid therapy initiation, and then after 15 and 33 days. Children with elevated IOP will continue ophthalmologists' follow up and treatment as necessary.

All parents or patients' guardians will sign informed consent for participating in the study.

The study group contains all newly diagnosed children with ALL in Schneider Children Medical Center.

Eligibility Criteria:
Inclusion Criteria:

* ALL diagnosis
* treated with an AIEOP-BFM protocol (including steroids)

Exclusion Criteria:

\* Any prior eye condition that can affect intra ocular pressure or its measurement
Efficacy of Morning-only Bowel Preparation for Afternoon Colonoscopy.

The study aims to study the adequacy of bowel preparation (colon cleansing) for afternoon colonoscopies. The conventional regimen of giving bowel prep on the evening prior to the day of the colonoscopy will be compared with that given on the morning of an afternoon colonoscopy. Endoscopist scoring the bowel cleansing efficacy with an Ottawa Scale are blinded to the randomization process.

Two bowel preparation regimens of Polyethylene Glycol (PEG), commonly referred to as "Golytely" will be tested for their efficacy (bowel cleansing effect) and patient tolerability. The goal is to reduce the failure rates of afternoon colonoscopies, for which, one of the main reasons attributed is inadequate bowel preparation. For the afternoon colonoscopies, the conventional PEG regimen given on the evening prior to the day of the colonoscopy will be compared with the novel PEG regimen given on the morning of the day of the colonoscopy. The comparison will be drawn for two measures - bowel cleansing effect measured from the questionnaire given to the gastroenterologists performing the colonoscopy and the patient tolerability evaluated from the information gathered from the patient's questionnaire.

Eligibility Criteria:
Inclusion Criteria:

* All patients attending the GI Clinic at CCF who are prescribed colonoscopy and are willing to get the procedure done in the afternoon.

Exclusion Criteria:

* Colonoscopy is contraindicated
* Prior Colectomy or colon surgery.
Mirvaso® Gel and Dysport® for Erythema and Flushing of Rosacea

To evaluate the safety and efficacy of Mirvaso® Gel and Dysport® for erythema and flushing of Rosacea.

To assess the improvement of facial erythema and flushing while using Mirvaso® and Dysport® treatments based on the clinician's and patient's assessments using a verified 5-point grading scale

Eligibility Criteria:
Inclusion Criteria:

1. Male or female
2. 18 years of age or older
3. Clinical diagnosis of rosacea
4. Moderate to severe persistent facial erythema associated with rosacea at baseline, as determined by: a grade of greater than or equal to 3 on the 5 point grading scale1 (Figure 1)
5. No known medical conditions that may interfere with study participation
6. Willingness to not use any products on their face for the duration of the study
7. Read, understand, and sign informed consent forms
8. Willingness to sign photography release form
9. Willing and able to comply with all follow-up requirements
10. Willingness to undergo treatment using Mirvaso® Gel and Dysport®

Exclusion Criteria:

1. Any significant skin disease at treatment area
2. Any medical condition which could interfere with the treatment
3. Inability or unwillingness to follow the treatment schedule
4. Inability or unwillingness to sign the informed consent
5. Pregnant or lactating
6. Allergy to cow's milk protein
7. Previous or current use of Mirvaso® Gel
8. Known hypersensitivity to Dysport® , Mirvaso® Gel or any of their ingredients
9. Previous Dysport® treatment 6 months prior to the screening visit
Effects of Stoss Therapy of Vitamin D3 on Peri-operative Outcomes in Patients Receiving General Surgery

To investigate whether preoperative supplement with high-dose vitamin D3 can reduce the perioperative risk and enhance recovery

Perioperative management for risk reduction in patients undergoing major surgery are taken increasingly important nowadays. The patient factor (age and comorbidities mainly), type of surgery and extent of tissue injury are major contributions to the development perioperative complications. From nutrition support to nutrition therapy, a comprehensive nutrition plays a pivotal role to optimize the above three key factors and hence reduce the perioperative risk. Vitamin D, a pleiotropic hormone with extensive physiological effect, is one of the nutrients critical to perioperative outcomes. It not only meets the essential demand of surgical patients, such as wound care, infection control, metabolic support and organ support, but also attenuates oxidative stress, modulates dys-inflammation and repair the damaged organelles like telomere and mitochondria. This is a double-blind, randomized controlled trial in a single center. Sixty eligible adult patients who will undergo general surgery are to be included.

The experimental group will receive 576000 IU in single oral dose of liquid vitamin D 3\~7 days prior to the surgery. The primary endpoint is rapid recovery index, such as bowel recovery, pain control, sedation and fatigue assessment. The secondary endpoints include perioperative inflammatory indexes, hemodynamic parameters, glycemic control as well as safety evaluation of vitamin D.

Eligibility Criteria:
Inclusion Criteria:

* 20 years or older
* Adult patients who will receive general surgery

Exclusion Criteria:

* Chronic liver diseases
* Hypercalcemia
* Using estrogen drug, bisphosphonate, other durgs to treat bone diseases
* Sarcoidosis, Multiple myeloma or Primary hyperparathyroidism
* Pregnant women
* Other trial participation